SkinRex issued FDA warning letter

January 8, 2014 by Chris Walker

SkinRex has been issued a FDA warning letter, concerning its marketing of Cavi-Lipo without approval or clearance.

SkinRex issued FDA warning letter

Korean cosmetic medical device company SkinRex Co. is in hot water with the FDA after the federal watchdog agency issued a warning letter over the marketing of its Cavi-Lipo device.

Seoul-based Skinrex is focused on skincare and weight issues. The company, founded in 2002, is led by Se-Yeong Choi and markets 3 products.

The Cavi-Lipo is an ultrasound cavitation system that uses ultrasound waves to dissolve cellulite and treat adipose areas. The device was launched in Japan in 2008 and won CE Mark approval in Europe in 2010, according to the SkinRex website.

Sign up to get our free newsletters delivered straight to your inbox

But the FDA says SkinRex never sought clearance or approval to put the Cavi-Lipo device on the U.S. market, according to the warning letter. The device does not have premarket approval or an investigational device exemption, making it illegal to be sold in the U.S., according to the letter, despite Internet reports and spa website descriptions identifying it as an “FDA Class 1” device.

The Cavi-Lipo device is also misbranded as an "electric therapeutic massager," according to the agency, which would exempt it from some regulatory requirements for medical devices. The FDA found that the device does not qualify as an electric therapeutic massager because it’s used “for the temporary reduction in the appearance of cellulite" using ultrasound diathermy, not "mechanical vibration to manipulate tissue," according to the letter.

Comments